Research programme: natural killer cell cancer therapies - NantKwest

Drug Profile

Research programme: natural killer cell cancer therapies - NantKwest

Alternative Names: CD19 target activated natural killer cellular therapy - NantKwest; CD19.taNK therapy - NantKwest; CS1 target activated natural killer cellular therapy- NantKwest; CS1.taNK therapy - NantKwest; CST 102; CST 103; HER2.tank; NANT Cancer Vaccine; NK 92 [CD16.158V, ER IL-2]; taNK cells; Target-activated natural killer cells; ZRx 102; ZRx 103; ZRx 104

Latest Information Update: 19 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZelleRx
  • Developer NantKwest
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 04 Apr 2017 NantKwest and Viracta Therapeutics enter into a collaboration agreement to investigate combination of natural killer cells and VRx 3996 in broad range of cancers
  • 04 Apr 2017 NantKwest plans clinical trials for haNK and taNK NK cell therapy in combination with VRx 3996
  • 15 Mar 2017 NantKwest announces intention to submit IND to US FDA for HER2.taNK for Solid tumours by mid-2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top